Big Pharma mergers

Merck's recent deal to buy Shering-Plough, and Pfizer's purchase of Wyeth, comes at a time of slumping sales in the drug industry and increased competition from generic drug makers. Midmorning looks at what these mergers mean for consumers and drug development, and examines how the drug industry could be affected by changes at the FDA.

Guests

• Stephen Schondelmeyer: head of the department of pharmaceutical care and health systems at the University of Minnesota.
• Howard Brody: professor of medicine and director of the Institute for the Humanities at the University of Texas Medical Branch.

Resources

• Stephen Schondelmeyer
• Howard Brody